Next Article in Journal
Inhaled Cisplatin for NSCLC: Facts and Results
Next Article in Special Issue
Transcriptomic Analysis Reveals Priming of The Host Antiviral Interferon Signaling Pathway by Bronchobini® Resulting in Balanced Immune Response to Rhinovirus Infection in Mouse Lung Tissue Slices
Previous Article in Journal
Nitrergic Enteric Neurons in Health and Disease—Focus on Animal Models
Previous Article in Special Issue
How to Process Sputum Samples and Extract Bacterial DNA for Microbiota Analysis
Open AccessReview

Biomarkers in Pneumonia—Beyond Procalcitonin

1
School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2
Clinic of Pulmonary Medicine and Respiratory Cell Research, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(8), 2004; https://doi.org/10.3390/ijms20082004
Received: 6 April 2019 / Revised: 21 April 2019 / Accepted: 22 April 2019 / Published: 24 April 2019
(This article belongs to the Special Issue Lung Infections: From Molecular Biology to Therapy)
Pneumonia is the leading infectious cause of mortality worldwide and one of the most common lower respiratory tract infections that is contributing significantly to the burden of antibiotic consumption. Due to the complexity of its pathophysiology, it is widely accepted that clinical diagnosis and prognosis are inadequate for the accurate assessment of the severity of the disease. The most challenging task for a physician is the risk stratification of patients with community-acquired pneumonia. Herein, early diagnosis is essential in order to reduce hospitalization and mortality. Procalcitonin and C-reactive protein remain the most widely used biomarkers, while interleukin 6 has been of particular interest in the literature. However, none of them appear to be ideal, and the search for novel biomarkers that will most sufficiently predict the severity and treatment response in pneumonia has lately intensified. Although our insight has significantly increased over the last years, a translational approach with the application of genomics, metabolomics, microbiomics, and proteomics is required to better understand the disease. In this review, we discuss this rapidly evolving area and summarize the application of novel biomarkers that appear to be promising for the accurate diagnosis and risk stratification of pneumonia. View Full-Text
Keywords: biomarkers; procalcitonin; pneumonia; novel biomarkers; procalcitonin; pneumonia; novel
MDPI and ACS Style

Karakioulaki, M.; Stolz, D. Biomarkers in Pneumonia—Beyond Procalcitonin. Int. J. Mol. Sci. 2019, 20, 2004.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop